Welcome to precisionFDA
Children's Hospital of Philadelphia
1. How might the pediatric cancer and rare disease community best engage the precisionFDA NGS assay development community and sponsor the further development of a sustainable compete-to-share ecosystem for collaborative discovery on behalf children?
2. How can the precisionFDA bioinformatics community be better empowered to partner with the pediatric cancer and rare disease community through a shared economy of accessible data and a shared interest in new models of attribution and/or reproducibility of results?